This is Episode 17: Definitive Chemo-RT Cisplatin is King. This episode is essential for boards. If you remember one thing from today, let it be this: *cisplatin is king*. Concurrent cisplatin with radiation is the standard of care for locally advanced head and neck cancer requiring systemic therapy—and multiple randomized trials have now proven that cetuximab is *not* an acceptable substitute, even though we once hoped it might be. We're going to work through the landmark trials that established concurrent chemoradiation, understand exactly which patients need systemic therapy and which don't, learn the framework for cisplatin-ineligible patients, dissect the cetuximab failures, and master dose-fractionation strategies. By the end, you'll be able to defend your treatment recommendations on oral boards with evidence-based precision.